Evidence map›Paper›PMID 35542629›Full record

ReviewRSC advances2019

Nanoparticle modification in biological media: implications for oral nanomedicines.

Vishnaka Muraleetharan, Julia Mantaj, Magda Swedrowska, Driton Vllasaliu

Abstract readReview
In one paragraph

Review in RSC advances, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Vishnaka MuraleetharanInstitute of Pharmaceutical Science, School of Cancer and Pharmaceutical Science, King's College London 150 Stamford Street London SE1 9NH UK Driton.vllasaliu@kcl.ac.uk.
Julia MantajInstitute of Pharmaceutical Science, School of Cancer and Pharmaceutical Science, King's College London 150 Stamford Street London SE1 9NH UK Driton.vllasaliu@kcl.ac.uk.
Magda SwedrowskaInstitute of Pharmaceutical Science, School of Cancer and Pharmaceutical Science, King's College London 150 Stamford Street London SE1 9NH UK Driton.vllasaliu@kcl.ac.uk.
Driton VllasaliuInstitute of Pharmaceutical Science, School of Cancer and Pharmaceutical Science, King's College London 150 Stamford Street London SE1 9NH UK Driton.vllasaliu@kcl.ac.uk.ORCID https://orcid.org/0000-0002-4379-6171

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nanomedicine has shown potential in enabling oral administration of poorly absorbable drugs, such as biologics. As part of the process related to optimisation of the safety and efficacy of nanomedicines, it is imperative that the interaction of nanoparticles with the biological systems - including the gut - is fully characterised. In this article, we provide an overview of the major mechanisms by which nanoparticles may transform upon introduction in biological media. Specifically, the phenomena of association, dissolution and biomolecule adsorption are discussed, together with factors which influence the occurrence of each phenomenon. The implications of these phenomena within the context of therapeutic action of nanomedicines, which includes reduced targeting efficiency, are also explored. Finally, we will comment on nanoparticle modification within the gut environment, including the currently available gastrointestinal models for the study of nano-bio interactions, with implications in the area of nanomedicines for oral administration.

Identifiers

PMID35542629
PMCPMC9076262

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.